Skip to main content

Advertisement

SpringerLink
Log in

Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Alzheimer’s dementia (AD) patients have profound deficits in cognitive and social functions, mediated in part by a decline in cholinergic function. Acetylcholinesterase inhibitors (AChEI) are the most commonly prescribed treatment for the cognitive deficits in AD patients, but their therapeutic effects are small, and it is still not clear if they primarily affect attention, memory, or some other cognitive/behavioral functions.

Objectives

The objective of the present experiments was to explore the effects of donepezil (Aricept™), an AChEI, on behavioral deficits related exclusively to cholinergic dysfunction.

Materials and methods

The effects of donepezil were assessed in Sprague–Dawley rats with scopolamine-induced deficits in a battery of cognitive/behavioral tests.

Results

Scopolamine produced deficits in contextual and cued fear conditioning, the 5-choice serial reaction time test, delayed nonmatching to position, the radial arm maze, and the Morris water maze. Analyses of the pattern and size of the effects revealed that donepezil produced very large effects on scopolamine-induced deficits in psychomotor function (∼20–50% of the variance), moderate-sized effects on scopolamine-induced deficits in simple conditioning and attention (∼3–10% of the variance), but only small effects on scopolamine-induced deficits in higher cognitive functions of working memory and spatial mapping (∼1% of the variance).

Conclusions

These results are consistent with the limited efficacy of donepezil on higher cognitive function in AD patients, and suggest that preclinical behavioral models could be used not only to determine if novel treatments have some therapeutic potential, but also to predict more precisely what the pattern and size of the effects might be.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F (2003) Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28:1235–1246

    Article  PubMed  CAS  Google Scholar 

  • Borkowska A, Ziolkowska-Kochan M, Rybakowski JK (2005) One-year treatment of Alzheimer’s disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. Hum Psychopharmacol 20:409–414

    Article  PubMed  CAS  Google Scholar 

  • Braida D, Paladini E, Griffini P, Lamperti M, Maggi A, Sala M (1996) An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 302:13–20

    Article  PubMed  CAS  Google Scholar 

  • Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988) Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26:685–700

    Article  PubMed  CAS  Google Scholar 

  • Bucks RS, Ashworth DL, Wilcock GK, Siegfried K (1996) Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 25:113–120

    PubMed  CAS  Google Scholar 

  • Chen Z, Xu AJ, Li R, Wei EQ (2002) Reversal of scopolamine-induced spatial memory deficits in rats by TAK-1471. Acta Pharmacol Sin 23:355–360

    PubMed  CAS  Google Scholar 

  • Cheng DH, Ren H, Tang XC (1996) Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 8:97–101

    PubMed  CAS  Google Scholar 

  • Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, New Jersey

    Google Scholar 

  • Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363:2105–2115

    Article  PubMed  CAS  Google Scholar 

  • Dawson GR, Iversen SD (1993) The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57:143–153

    Article  PubMed  CAS  Google Scholar 

  • Dooley M, Lamb HM (2000) Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging 16:199–226

    Article  PubMed  CAS  Google Scholar 

  • Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  PubMed  CAS  Google Scholar 

  • Gallagher M, Burwell R, Burchinal M (1993) Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci 107:618–626

    Article  PubMed  CAS  Google Scholar 

  • Hamann S, Monarch ES, Goldstein FC (2002) Impaired fear conditioning in Alzheimer’s disease. Neuropsychologia 40:1187–1195

    Article  PubMed  Google Scholar 

  • Higgins GA, Enderlin M, Fimbel R, Haman M, Grottick AJ, Soriano M, Richards JG, Kemp JA, Gill R (2002) Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Eur J Neurosci 15:1827–1840

    Article  PubMed  CAS  Google Scholar 

  • Hutchison CW, Nathan PJ, Mrazek L, Stough C (2001) Cholinergic modulation of speed of early information processing: the effect of donepezil on inspection time. Psychopharmacology (Berl) 155:440–442

    Article  CAS  Google Scholar 

  • Jones DN, Higgins GA (1995) Effect of scopolamine on visual attention in rats. Psychopharmacology (Berl) 120:142–149

    Article  CAS  Google Scholar 

  • Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 331:321–327

    Article  PubMed  CAS  Google Scholar 

  • Kirkby DL, Jones DN, Barnes JC, Higgins GA (1996) Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 7:513–525

    PubMed  CAS  Google Scholar 

  • Kluger A, Gianutsos JG, Golomb J, Ferris SH, George AE, Franssen E, Reisberg B (1997a) Patterns of motor impairment in normal aging, mild cognitive decline, and early Alzheimer’s disease. J Gerontol B Psychol Sci Soc Sci 52:28–39

    Google Scholar 

  • Kluger A, Gianutsos JG, Golomb J, Ferris SH, Reisberg B (1997b) Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer’s disease: diagnostic and differential diagnostic features. Int Psychogeriatr 9:307–316

    Article  PubMed  Google Scholar 

  • Kmietowicz Z (2005) NICE proposes to withdraw Alzheimer’s drugs from NHS. BMJ 330:495

    Article  PubMed  Google Scholar 

  • Lawrence AD, Sahakian BJ (1995) Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 9:43–49

    PubMed  Google Scholar 

  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34:939–944

    PubMed  CAS  Google Scholar 

  • Muller G, Richter RA, Weisbrod S, Klingberg F (1991) Reaction time prolongation in the early stage of presenile onset Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 241:46–48

    Article  PubMed  CAS  Google Scholar 

  • National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DC

    Google Scholar 

  • Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 22:89–95

    Article  PubMed  CAS  Google Scholar 

  • Perry EK, Perry RH, Gibson PH, Blessed G, Tomlinson BE (1977) A cholinergic connection between normal aging and senile dementia in the human hippocampus. Neurosci Lett 6:85–89

    Article  CAS  PubMed  Google Scholar 

  • Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 2:1457–1459

    Article  PubMed  CAS  Google Scholar 

  • Peters BH, Levin HS (1979) Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol 6:219–221

    Article  PubMed  CAS  Google Scholar 

  • Poorheidari G, Stanhope KJ, Pratt JA (1998) Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Psychopharmacology (Berl) 135:242–255

    Article  CAS  Google Scholar 

  • Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163:362–380

    Article  CAS  Google Scholar 

  • SAS Institute (1999) SAS/STAT user’s guide, Version 8. SAS Institute, Cary, North Carolina

    Google Scholar 

  • Sinson G, Voddi M, McIntosh TK (1995) Nerve growth factor administration attenuates cognitive but not neurobehavioral motor dysfunction or hippocampal cell loss following fluid-percussion brain injury in rats. J Neurochem 65:2209–2216

    Article  PubMed  CAS  Google Scholar 

  • Smith CM, Swash M (1978) Possible biochemical basis of memory disorder in Alzheimer disease. Ann Neurol 3:471–473

    Article  PubMed  CAS  Google Scholar 

  • Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA, Cohen RM (1986) Pharmacologic modelling of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 10:599–610

    Article  PubMed  CAS  Google Scholar 

  • Tokita K, Yamazaki S, Yamazaki M, Matsuoka N, Mutoh S (2002) Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav 73:511–519

    Article  PubMed  CAS  Google Scholar 

  • Wang T, Tang XC (1998) Reversal of scopolamine-induced deficits in radial maze performance by (−)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 349:137–142

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi Y, Higashi M, Matsuno T, Kawashima S (2001) Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol 87:240–244

    Article  PubMed  CAS  Google Scholar 

  • Zec RF, Landreth ES, Vicari SK, Belman J, Feldman E, Andrise A, Robbs R, Becker R, Kumar V (1992a) Alzheimer disease assessment scale: a subtest analysis. Alzheimer Dis Assoc Disord 6:164–181

    Article  PubMed  CAS  Google Scholar 

  • Zec RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R (1992b) Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 6:89–102

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department 401, Neuroscience Drug Discovery, Bristol–Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT, 06492, USA

    Mark D. Lindner, John B. Hogan, Donald B. Hodges Jr, Anitra F. Orie, Ping Chen, Jason A. Corsa, John E. Leet, Kevin W. Gillman, Gregory M. Rose, Kelli M. Jones & Valentin K. Gribkoff

Authors
  1. Mark D. Lindner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John B. Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald B. Hodges Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anitra F. Orie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ping Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jason A. Corsa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John E. Leet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kevin W. Gillman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gregory M. Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kelli M. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Valentin K. Gribkoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark D. Lindner.

Electronic supplementary material

Below is the link to the electronic supplementary material.

(DOC 252 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindner, M.D., Hogan, J.B., Hodges, D.B. et al. Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology 188, 629–640 (2006). https://doi.org/10.1007/s00213-006-0556-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-006-0556-3

Keywords

Search

Navigation